3 results
Approved WMOCompleted
To assess sorafenib pharmacokinetics and biodistribution, K-Ras mutational status, tumor uptake and tumor response in NSCLC patients.
Approved WMOCompleted
The primary hypothesis of this study is that ibrutinib compared with temsirolimus significantly prolongs PFS in subjects with relapsed or refractory MCL who have received at least 1 prior rituximab-containing chemotherapy regimen.
Approved WMORecruiting
The aim of this phase 2 study is to investigate the safety and efficacy of dazucorilant in the target ALS patient population.